CHICAGO (March 24, 2014) – Ulmer & Berne LLP announces the addition of accomplished litigator David D. Pope as a partner in the firm’s Chicago office. Mr. Pope, who joins Ulmer & Berne after spending the last 13 years at Mayer Brown LLP, adds increased depth and focus to the firm’s nationally recognized litigation team.

“David has earned a reputation as an outstanding and well-rounded litigator,” said Randall Lehner, partner-in-charge of Ulmer & Berne’s Chicago office. “His client-focused and business-oriented approach to the practice of law is a perfect fit for our clients, and I know that our clients will be well-served by the caliber of his experience and the value of his judgment.”

Mr. Pope is a commercial litigator who focuses his practice on the financial services industry. Since 2001, he has represented banks and other financial institutions in a wide variety of complex litigation throughout the country. Mr. Pope defends clients in consumer class actions involving financial products in retail banking. He also handles securities class actions and SEC investigations for public companies. In addition to his experience with financial services firms, Mr. Pope represents a variety of businesses in other industries, both large and small, in litigation involving breaches of contract, intellectual property, construction, real estate, and product liability.

Mr. Pope earned his B.A., magna cum laude, from Colorado College and his J.D. from the University of Chicago Law School.

About Ulmer & Berne LLP

Ulmer & Berne, established in 1908, is a full-service law firm focused on exceeding client expectations and delivering superior, customized legal solutions for an exceptional value. Its more than 180 attorneys, located in Chicago, Cincinnati, Cleveland and Columbus, serve as counselors and partners to a wide range of clients to help them solve their business challenges and achieve their goals. The firm represents publicly traded and privately held companies, financial institutions, hedge funds, private equity funds, pharmaceutical companies, international joint ventures and affiliations, investor groups, family offices, start-ups and emerging businesses, public bodies and nonprofit organizations. For more information, please visit